Protecting the blood supply from emerging pathogens: the role of pathogen inactivation

scientific article

Protecting the blood supply from emerging pathogens: the role of pathogen inactivation is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1016/J.TMRV.2004.11.005
P932PMC publication ID7126528
P698PubMed publication ID15852240
P5875ResearchGate publication ID7886119

P50authorMichael P. BuschQ6833284
David A LeibyQ90319989
Celso BiancoQ114430369
Susan L StramerQ66751416
P2093author name stringLily Lin
Mark E Brecher
Morris A Blajchman
Jean Pierre Allain
P2860cites workChronic wasting disease and potential transmission to humansQ24599755
Transfusion-associated babesiosis after heart transplantQ24610281
Detection of Babesia microti by polymerase chain reactionQ24658352
Eliminating Trachoma in Areas with Limited DiseaseQ29037878
Avian influenza and human health.Q30330442
Nucleic acid testing for emerging viral infectionsQ30721623
Identification and characterization of putative secreted antigens from Babesia microtiQ30885688
First results using automated epifluorescence microscopy to detect Escherichia coli and Staphylococcus epidermidis in WBC-reduced platelet concentratesQ32040603
Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control StudyQ33338131
Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trialQ33345486
Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpuraQ33348253
Transfusion-transmitted babesiosis in Ontario: first reported case in CanadaQ73460291
Detection of bacteria in WBC-reduced PLT concentrates using percent oxygen as a marker for bacteria growthQ73811096
Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collectionsQ74418641
HBV: amplified and back in the blood safety spotlightQ74500188
Fatal Clostridium perfringens sepsis from a pooled platelet transfusionQ74503592
Dengue fever on the increaseQ74539620
Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipientsQ77451463
Parvovirus B19 DNA in plasma pools and plasma derivativesQ77793402
Inactivation of HIV in bloodQ78493198
From the Centers for Disease Control and Prevention. Investigations of West Nile virus infections in recipients of blood transfusionsQ78611566
Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coatsQ95719295
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialQ33360736
Approaches to the detection of bacterial contamination in cellular blood productsQ33602575
Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reportsQ33623655
Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United StatesQ33875842
The use of dimethylmethylene blue for virus photoinactivation of red cell suspensionsQ33900392
Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donorQ33978508
The use of riboflavin for the inactivation of pathogens in blood productsQ34000406
Human babesiosis: an emerging tick-borne diseaseQ34102705
Incidence and significance of the bacterial contamination of blood components.Q34148581
Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and lightQ34322353
Medically important arboviruses of the United States and CanadaQ34336519
Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patientQ34339769
Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspectiveQ34451441
Bacterial contamination of platelet concentrates: incidence, significance, and preventionQ34451446
Inactivation of cytomegalovirus in platelet concentrates using Helinx technologyQ34451451
Virus inactivation in blood components by photoactive phenothiazine dyesQ34491789
Bacterial contamination of blood products: factors, options, and insightsQ34522392
Viral meningitis and encephalitis: traditional and emerging viral agentsQ34535781
Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizerQ34996364
Transfusion medicine: looking to the futureQ35047211
Transmission of viral hepatitis by blood and blood derivatives: current risks, past heritage.Q35052861
Safety of the blood supply: role of pathogen reductionQ35087058
Airport malaria: report of a case and a brief review of the literature.Q35103177
Risks associated with transfusion of cellular blood components in canadaQ35122220
Pathogen reduction technology: methods, status of clinical trials, and future prospectsQ35560787
Severe acute respiratory syndrome (SARS)--paradigm of an emerging viral infection.Q35607877
Improving the bacteriological safety of platelet transfusionsQ35613174
Viral hepatitis: from A to E, and beyond?Q35613967
Improving platelet safety: bacterial contamination of plateletsQ35668474
Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusionQ38473724
Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.Q39740523
Local transmission of Plasmodium vivax malaria--Palm Beach County, Florida, 2003Q40549714
Transmission of West Nile Virus through Blood Transfusion in the United States in 2002Q40550030
West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivationQ40554292
Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998.Q40571207
Identification of Babesia microti-specific immunodominant epitopes and development of a peptide EIA for detection of antibodies in serumQ40622880
Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistryQ40689418
Transfusion-associated Chagas' disease in Texas: report of a caseQ40750204
Rocky mountain spotted fever caused by blood transfusionQ40875178
Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteriaQ41461282
Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.Q41468943
The use of a chemiluminescence‐linked universal bacterial ribosomal RNA gene probe and blood gas analysis for the rapid detection of bacterial contamination in white cell‐reduced and nonreduced plateletsQ41503213
Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donorsQ42665299
Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasmaQ42980958
Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet lightQ42982277
Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA.Q42996768
Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studiesQ43037065
Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor populationQ43040535
SEN virus infection and its relationship to transfusion-associated hepatitisQ43601229
Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet functionQ43655377
Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United StatesQ43727179
Duck hepatitis B photoinactivation bydimethylmethylene blue in RBC suspensionsQ43734115
Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donorsQ43740289
Use of riboflavin for photoinactivation of pathogens in blood componentsQ43887055
Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical studyQ43918917
Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window periodQ44170176
Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarinQ44210527
First report of human immunodeficiency virus transmission via an RNA-screened blood donationQ44326279
Transmission of parasites by blood transfusionQ44368419
A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated plateletsQ44579149
Transfusion-associated acute Chagas disease acquired in the United StatesQ45031981
Virus photoinactivation in stroma-free hemoglobin with methylene blue or 1,9-dimethylmethylene blueQ45744856
Virus Inactivated Single-Donor Fresh Plasma PreparationsQ45865281
Current and emerging infectious risks of blood transfusionsQ46883397
Inactivation of mycoplasma species in blood by INACTINE PEN110 process.Q47206402
Pathogen inactivation of RBCs: PEN110 reproductive toxicology studiesQ47608681
Single-donor platelets reduce the risk of septic platelet transfusion reactionsQ49166133
Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB.Q50509806
Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma.Q50517766
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.Q51037857
Electrochemiluminescent detection of bacteria in blood components.Q52545960
Development of a sensitive PCR inhibition method to demonstrate HBV nucleic acid inactivation.Q52842012
Inactivation of parvovirus B19 during pasteurization of human serum albumin.Q53955493
Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS)Q55239955
From the Centers for Disease Control and Prevention. Local transmission of Plasmodium vivax malaria--Virginia 2002Q56447274
Transfusion-associated Trypanosoma cruzi infection in a non-endemic areaQ58845305
Prospective evaluation of a patient with Trypanosoma cruzi infection transmitted by transfusionQ58847043
Evaluation of a reporting system for bacterial contamination of blood components in the United StatesQ64128634
Parvovirus B19 infectionQ71103605
[First documentation of transfusion-associated babesiosis in Japan]Q73046346
Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activityQ73205703
Rapid identification of bacterially contaminated platelets using reagent strips: glucose and pH analysis as markers of bacterial metabolismQ73277637
Evaluation of donor skin disinfection methodsQ73277667
Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donationsQ73402681
P433issue2
P921main subjectemerging pathogenQ108429945
P304page(s)110-126
P577publication date2005-04-01
P1433published inTransfusion Medicine ReviewsQ15758511
P1476titleProtecting the blood supply from emerging pathogens: the role of pathogen inactivation.
P478volume19

Reverse relations

cites work (P2860)
Q47556754Amustaline (S-303) treatment inactivates high levels of Chikungunya virus in red-blood-cell components.
Q28729789Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components
Q93541706Bacterial contamination of platelet concentrates: pathogen detection and inactivation methods
Q37715077Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality
Q37589285Consensus and controversies in platelet transfusion
Q38332335Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands
Q41452764Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation
Q91955390Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study
Q50201431Healing of a soft tissue wound of the neck and jaw osteoradionecrosis using platelet gel.
Q26741073Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use
Q50563846Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
Q33852543Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.
Q42236941Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions.
Q50705094Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model.
Q22330681Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination
Q38158233Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination
Q39284167Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination
Q38667338Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria
Q33396311Main Properties of the THERAFLEX MB-Plasma System for Pathogen Reduction
Q33397396Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system
Q34006006Microcalorimetry: a novel method for detection of microbial contamination in platelet products
Q35095646Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™
Q41935541Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione
Q43807105Pathogen inactivation of platelets: organization consequences for platelet transfusion
Q37013124Pathogen inactivation: making decisions about new technologies. Report of a consensus conference
Q28544736Pathogen reduction in human plasma using an ultrashort pulsed laser
Q50655717Pathogen reduction: a precautionary principle paradigm.
Q26739936Platelet gel: a new therapeutic tool with great potential
Q46356432Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment
Q92597042Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione
Q39263574Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system
Q38220202Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion
Q28733459Prevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivation
Q37595112Problem of bacterial contamination in platelet concentrates
Q83795700Protecting the blood supply from emerging pathogens: the role of pathogen inactivation
Q38084362Proteomics applied to transfusion plasma: the beginning of the story
Q50217763Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies
Q37062415Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma
Q47572436Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment
Q91471131Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes
Q33394967Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients
Q45357266Simultaneous triple point-of-care testing for HIV, syphilis and hepatitis B virus to prevent mother-to-child transmission in India.
Q24614152The influence of riboflavin photochemistry on plasma coagulation factors
Q37798900The status of pathogen-reduced plasma
Q27480405Transfusion-transmitted infections
Q39847980Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series
Q33370956Treatment of thrombotic thrombocytopenic purpura.
Q33394914Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion
Q37809341Umbilical Cord Blood Transplantation for Thalassemia Major
Q37166900Updates on pathogen inactivation of plasma using Theraflex methylene blue system
Q33788326Use of hemovigilance data to evaluate the effectiveness of diversion and bacterial detection
Q37671773Why implement universal leukoreduction?
Q24261255Zika Virus

Search more.